Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun;7(2):183-195.
doi: 10.1007/s40121-018-0201-6. Epub 2018 May 14.

A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population

Affiliations
Review

A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population

Anita Chawla et al. Infect Dis Ther. 2018 Jun.

Abstract

Human immunodeficiency virus (HIV) is a chronic infectious disease currently requiring lifelong antiretroviral therapy (ART). People living with HIV (PLWH) face an increased risk of comorbidities associated with aging, chronic HIV, and the toxicity arising from long-term ART. A literature review was conducted to identify the most recent evidence documenting toxicities associated with long-term ART, particularly among aging PLWH. In general, PLWH are at a greater risk of developing fractures, osteoporosis, renal and metabolic disorders, central nervous system disorders, cardiovascular disease, and liver disease. There remains limited evidence describing the economic burden of long-term ART. Overall, an aging HIV population treated with long-term ART presents a scenario in which the clinical, humanistic, and economic burden for healthcare systems will demand thoughtful policy solutions that preserve access to treatment. Newer treatment regimens with fewer drugs may mitigate some of the cumulative toxicity burden of long-term ART.Funding: ViiV Healthcare.

Keywords: Aging; Antiretroviral therapy; HIV/AIDS; Toxicity; Two-drug regimen.

PubMed Disclaimer

Similar articles

Cited by

References

    1. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS. 2014;28(8):1193–1202. doi: 10.1097/QAD.0000000000000243. - DOI - PMC - PubMed
    1. Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP, Jr, Klein DB, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016;73(1):39–46. doi: 10.1097/QAI.0000000000001014. - DOI - PMC - PubMed
    1. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533. doi: 10.1016/S0140-6736(13)61809-7. - DOI - PMC - PubMed
    1. European AIDS Clinical Society. Guidelines version 9.0. October 2017. http://www.eacsociety.org/files/guidelines_9.0-english.pdf. Accessed 1 May 2018.
    1. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. March 27, 2018. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 1 May 2018.

LinkOut - more resources